Find a Doctor

Rolf A. Stahel

University Hospital Zurich
Male

Bio


He has been an author on 187 peer reviewed articles in the past 15 years.

Contact

CH

Latest Research


Latest Advance
Study
  • Condition: Malignant Pleural Mesothelioma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Pembrolizumab versus Single-Agent Chemotherapy
  • Number of Patients: 144
  • Published —
The study researched the outcomes of pembrolizumab versus single-agent chemotherapy for treating malignant pleural meosthelioma.
Latest Advance
Study
  • Condition: Stage III Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Nivolumab added Concurrently to Radiotherapy in a Standard First Line Chemo-Radiotherapy (CRT) Regimen
  • Number of Patients: 82
  • Published —
This study evaluated the safety and effectiveness of nivolumab combined with chemo-radiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Non-Small Cell Lung Cancer with HER2 Mutations
  • Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • Treatment Used: Afatinib
  • Number of Patients: 13
  • Published —
The purpose of the study was to assess the effectiveness of Afatinib in non-small cell lung cancer with HER2 mutations.
Latest Advance
Study
  • Condition: HER2-Positive Non-Small Cell Lung Cancer
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Trastuzumab Emtansine
  • Number of Patients: 49
  • Published —
In this study, researchers evaluated the safety and effectiveness of trastuzumab emtansine for the treatment of HER2-positive non-small cell lung cancer.

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Publication
Study
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Published —
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.

Contact

CH

Insurance

Contact them to find out if they accept your insurance plan.